November 25, 2025

Cognitive Function and Statin Administration During Doxorubicin-Based Cancer Treatment

Contrary to previous research, a preplanned secondary analysis of the multicenter PREVENT trial, reported by W.Gregory Hundley, MD, FACC, of Pauley Heart Center, Division of Cardiology, Department of ...

The ASCO Post

November 25, 2025

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients...

The ASCO Post

November 24, 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistical...

The ASCO Post

November 19, 2025

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma.

The ASCO Post

November 19, 2025

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published i...

The ASCO Post

November 19, 2025

New Study Explores Why Male Patients With AML May Have Worse Outcomes

New research has ruled out hormone signaling as the reason why men with AML tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine ...

The ASCO Post

November 19, 2025

Lung Cancer Treatment Evolutions Include Surgical Innovation and Molecular Targeted Therapy

Lung cancer survival rates have approximately doubled over the past two decades — a remarkable achievement driven by convergent advances in early detection, surgical technique and molecular oncology.

Baptist Health South Florida

November 19, 2025

Project ASCENT: Advancing Lung Cancer Screening in Hispanic Populations

Lung cancer remains the leading cause of cancer mortality in the United States, surpassing the combined deaths of breast, colon and prostate cancers.

Baptist Health South Florida

November 18, 2025

Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer

In a Canadian phase III trial (MAST) reported in the Journal of Clinical Oncology, Fleshner et al found that metformin did not improve progression-free survival vs placebo in men with low-risk prostat...

The ASCO Post